Rohto Pharmaceutical Co., Ltd. 4527
TSE · Japan · Consumer Non-Durables
¥2,790.00-30.00 (-1.06%)
Market open· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co., LTD, a Japanese multinational corporation specializing in consumer products and pharmaceuticals, with a primary focus on eye care.
Rohto PharmaceuticalLtd (TSE:4527) is back in focus after the board approved a higher year end dividend from retained earnings and reaffirmed its dividend approach alongside fresh earnings guidance and responses to shareholder proposals. See our latest analysis for Rohto PharmaceuticalLtd. The recent dividend increase, fresh earnings guidance and board responses to activist proposals have coincided with a 1 month share price return of 8.76% and a 1 year total shareholder return of 26.75%. At...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.